Biotron Ltd (BIT)

Snapshot

BIT's Principal Activity is the funding and management of intermediate and applied biotechnology research and development projects.

Announcements

Corporate Overview

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date	Amount	Franking	Gross	Type	Payable
No dividends paid.

Show All

See Upcoming Dividends for all ASX companies.

Directors & Management

Name	Title	Since	Bio
Professor Stephen Alister Locarnini	Non-Executive Director	Oct 2018	Professor Stephen Alister Locarnini Non-Executive Director Prof Locarnini is a past director of the World Health Organisation (WHO) Regional Reference Laboratory for Hepatitis B and D for the Western Pacific Region (WPRO). He is a named inventor on over 20 internationally granted patents. He worked at the Victorian Infectious Diseases Reference Laboratory (VIDRL, originally Fairfield Hospital Virus Laboratory) from 1989, as Director of Laboratory Services from 1990 to 1998 and, in 1993, he oversaw the amalgamation of all the Fairfield Laboratories into the one service of the VIDRL. He subsequently assumed the position of Head, Research & Molecular Development of VIDRL when the laboratory relocated to Melbourne Health in 1998. Professor Locarnini currently has an academic appointment at the University of Melbourne. He is a member of the Scientific Advisory Board of a number of emerging as well as established pharmaceutical and biotechnology companies. In 2017, he co-founded the biotech start-up company CLEAR-B with the Morningside-Newton Investment group in Boston, USA focusing on curative strategies for chronic hepatitis B.
Mr Robert Bain Thomas	Non-Executive Director	Mar 2012	Mr Robert Bain Thomas Non-Executive Director Mr Thomas has over 35 years of experience in the securities industry, with Potter Partners (now UBS), County NatWest and Citigroup. He is the chairman of Starpharma Holdings Limited and a director of Clarity Pharmaceuticals Limited. He chairs Grahger Retail Securities Pty Ltd and is a director of O'Connell Street Associates Pty Limited.
Dr Susan Margaret Pond	Non-Executive Director	Mar 2012	Dr Susan Margaret Pond Non-Executive Director Dr Pond has a scientific and commercial background having held executive positions in the biotechnology and pharmaceutical industry for 12 years, most recently as chairman and managing director of Johnson & Johnson Research Pty Limited (2003 - 2009). Previous non-executive positions include chair of AusBiotech Limited and director of Australian Nuclear Science and Technology Organisation, Wound Management Innovation CRC and Australian Academy of Technological Sciences and Engineering (ATSE). Dr Pond also served as a board member of Commercialisation Australia and Innovation Australia. Dr Pond is currently chair of the New South Wales Smart Sensing Network, director of the Trusted Autonomous Systems Defence Cooperative Research Centre, Vectus Biosystems Ltd, Cannatrek Ltd and the Australian Phenomics Network and Governor in Council of the Queensland University of Technology.
Dr Michelle Miller	Managing Director	Jun 2002	Dr Michelle Miller Managing Director Dr Miller has worked for over 25 years in the bioscience industry, with experience in commercial drug development. Her experience includes several years at Johnson & Johnson developing antiHIV gene therapeutics through preclinical research to clinical trials. She has finance industry experience from time spent as an Investment Manager with a bioscience venture capital fund.
Mr Michael J Hoy	Non-Executive Director,Non-Executive Chairman	Feb 2000	Mr Michael J Hoy Non-Executive Director,Non-Executive Chairman Mr Hoy has more than 30 years of corporate experience in Australia, the United Kingdom, USA and Asia. He is Chairman of Lipotek Pty Limited and a former director of John Fairfax Holdings Limited and FXF Trust.
Mr Peter James Nightingale	Company Secretary	Feb 1999

Show All

Director Transactions

Date	Director	Type	Amount	Price	Value	Notes
22/01/20	Robert Thomas	Buy	+1,000,000	$0.05	$50,000	Off-market trade
10/01/20	Stephen Locarnini	Buy	+800,000	$0.05	$40,000	Off-market trade
10/01/20	Stephen Locarnini	Buy	+800,000	$0.05	$40,000	Off-market trade
23/12/19	Michelle Miller	Issued	7,000,000	$0.055	$385,000	Issue of options
05/12/19	Susan Pond	Buy	+109,049	$0.05	$5,452	Exercise of options
05/12/19	Susan Pond	Exercise	109,049	$0.05	$5,452	Exercise of options
05/12/19	Michelle Miller	Transfer	1,500,000	$0.06	$90,000	Off-market transfer
05/12/19	Michelle Miller	Buy	+190,625	$0.05	$9,531	Exercise of options
05/12/19	Michelle Miller	Exercise	190,625	$0.05	$9,531	Exercise of options
05/12/19	Michelle Miller	Transfer	1,500,000	$0.06	$90,000	Off-market transfer
07/11/19	Michael Hoy	Exercise	1,557,965	$0.05	$77,898	Exercise of options
07/11/19	Michael Hoy	Buy	+1,557,965	$0.05	$77,898	Exercise of options

Show All

Director Interests

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
Stephen Locarnini	30/06/2021	N/A	800,000	N/A	N/A
Susan Pond	30/06/2021	N/A	654,295	N/A	N/A
Michelle Miller	30/06/2021	1,656,250	1,500,000	7,000,000	N/A
Robert Thomas	30/06/2021	N/A	3,663,195	N/A	N/A
Michael Hoy	30/06/2021	N/A	9,347,793	N/A	N/A

Show All

Top 20 Shareholders

About the Data

Name	Shares	Capital
Jey Investment Pty Ltd	14,440,945	2.06%
Dr Angela Fay Dulhunty	10,000,000	1.42%
Umbiram Pty Ltd <Michael Hoy Super Fund A/C>	9,347,793	1.33%
Citicorp Nominees Pty Limited	8,427,055	1.20%
Jimmy Thomas and Ivy Ruth Ponniah	8,372,057	1.19%
DNS Accounting and Law Consultancy Pty Ltd	8,254,558	1.18%
Armco Barriers Pty Ltd	7,000,000	1.00%
Fordholm Investments Pty Ltd <Fordholm Super Fund A/C>	7,000,000	1.00%
Rookharp Capital Pty Limited	7,000,000	1.00%
Pathold No 222 Pty Ltd	5,250,000	0.75%
Scott s A V Pty Ltd <Scotts Acorn EMP S/F A/C>	4,918,000	0.70%
Edstop Pty Limited <Superannuation Fund A/C>	4,571,588	0.65%
William John Dunn	4,400,000	0.63%
Attollo Copia Pty Ltd <F A Pires Super Fund A/C>	4,300,565	0.61%
Travis Paul Gloury	3,779,784	0.54%
Robert Thomas and Kyrenia Thomas <Rob Thomas Super Fund A/C>	3,663,195	0.52%
Dr Sanjiv Pathak	3,632,313	0.52%
Peter James Nightingale	3,594,903	0.51%
Alpha Matilda Trading Pty Ltd <Alpha Matilda Superfund A/C>	3,337,472	0.48%
Mark Andrew Peterson	3,332,000	0.47%

Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Substantial Shareholders

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Full Month

Historical Data

Year	Closing Price	Last Trade
2020	$0.074	30 June
2019	$0.066	28 June
2018	$0.019	29 June
2017	$0.02	28 June
2016	$0.06	28 June
2015	$0.125	30 June
2014	$0.105	30 June

BIT Historical Price Data (CSV)

Up to 20 years of EOD share price history

Sign up to Download

You must be logged in to access this feature. Please sign up for free or login.